Abstract. Target identification remains a crucial challenge in drug development. To enable 24 unbiased detection of proteins and pathways that have a causal role in disease pathogenesis 25 or progression, we propose proteome-by-phenome Mendelian Randomisation (P 2 MR). We 26 first detected genetic variants associated with plasma concentration of 249 proteins. We 27 then used 64 replicated variants in two-sample Mendelian Randomisation to quantify 28 evidence of a causal role for each protein across 846 phenotypes: this yielded 509 robust 29 protein-outcome links. P 2 MR provides substantial promise for drug target prioritisation. We 30 provide confirmatory evidence for a causal role for the proteins encoded at multiple 31 cardiovascular disease risk loci (FGF5, IL6R, LPL, LTA), and discovered that intestinal fatty 32 acid binding protein (FABP2) contributes to disease pathogenesis. Additionally, we find and 33 replicate evidence for a causal role of tyrosine-protein phosphatase non-receptor type 34 substrate 1 (SHPS1; SIRPA) in schizophrenia. Our results provide specific prediction of the 35 effects of changes of plasma protein concentration on complex phenotypes in humans. 36 37 An initial goal of drug development is the identification of targets -in most cases, proteins -38 whose interaction with a drug ameliorates the development, progression, or symptoms of 39 disease. After some success, the rate of discovery of new targets has not accelerated despite 40 substantially increased investment (Munos, 2009) . A large proportion of drugs fail at the last 41 stages of development -clinical trials -because their targets do not alter whole-organism 42 phenotypes as expected from pre-clinical research (Arrowsmith, 2011). 43
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there is little justification to undertake an adequately powered randomised control trial of a 322 drug targeting a protein for which there is minimal evidence of a link between that protein 323 and disease. P 2 MR does not suffer from such limitations. percentage. This is an association already realised in one of the phase II clinical trials 336 investigating dupilumab in asthma: a rise in eosinophil count was observed for some 337 patients, even leading to the withdrawal of one patient from the study (Wenzel et al., 2016 (Wenzel et al., , 338 2013 
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